Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma

已完结 10 由诗奕发布于 2024/11/4 20:17:36

DOI:10.1038/s41591-022-01868-2
作者：Andrew X. Zhu, Alexander R. Abbas, Marina Ruiz de Galarreta, Yinghui Guan, Shan Lu, Hartmut Koeppen, Wenjun Zhang, Chih-Hung Hsu, Aiwu Ruth He, Baek-Yeol R
文献类型：期刊论文
补充材料：只需要正文

Nature

Abstract：Atezolizumab (anti-programmed death-ligand 1 (PD-L1)) and bevacizumab (anti-vascular endothelial growth factor (VEGF)) combination therapy has become the new standard of care in patients wit

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:其它数据库Antioxidant activity assessment of Yingjisha sweet almond oil